Why consider FASLODEX
Clinical trial data
In a clinical study, the 500-mg dose of FASLODEX was compared to the original 250-mg dose, among 736 postmenopausal women with hormone receptor-positive metastatic breast cancer. In these women, the disease had returned or progressed on antiestrogen medicine or after previous treatment with antiestrogen medicine. The patients were randomly assigned to receive FASLODEX 500 mg or FASLODEX 250 mg. The study established that the 500-mg dose reduced the risk of disease progression by 20% compared to the 250-mg dose. The study also established that the side effect profile of the 500-mg dose was comparable to that of the 250-mg dose.
Previous clinical trials
The safety and effectiveness of FASLODEX was previously established in clinical trials comparing FASLODEX 250 mg with ARIMIDEX® (anastrozole) Tablets, another hormonal treatment. These studies included postmenopausal women whose metastatic breast cancer recurred or progressed after previous treatment with hormonal therapy.
See how FASLODEX works
Learn about taking FASLODEX
FASLODEX is a prescription medicine used to treat hormone receptor-positive breast cancer in women who have gone through menopause whose disease has spread after treatment with antiestrogen medicine.
IMPORTANT SAFETY INFORMATION: You should not receive FASLODEX if you have had an allergic reaction to any of the ingredients in FASLODEX. Symptoms of an allergic reaction to FASLODEX may include itching, swelling of your face, lips, tongue, or throat, or trouble breathing.
Click Here for
Additional Safety Information